Fenwick Represents Sierra Oncology in $103 Million Public Offering of Convertible Preferred Stock and Warrants

Fenwick & West represented Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, in its underwritten public offering of Series A convertible preferred stock, together with Series A warrants and Series B warrants, each to purchase shares of common stock, with gross proceeds to Sierra Oncology of $103 million.

Jefferies acted as the sole book-running manager for the offering. Oppenheimer & Co. acted as lead manager for the offering.

The Fenwick transaction team was led by corporate partners Robert Freedman, Stephen Graham and Amanda Rose, associates Ryan Mitteness, Alice Lin, Chelsea Anderson, Derrick Chapman and John Clancy; and intellectual property partner Daniel Becker and associate Andrea Nichols.